Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P050038/S043

Arista AH

Davol, Inc. · Decision date Apr 29, 2026

FDA DECISIONP050038/S043

What did the FDA decide?

FDA records P050038/S043 as a supplement to PMA P050038, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 29, 2026.

FDA approval order statement

installation of new equipment to automate the filling/weighing and label-application processes, as well as for the upgrade of the HVAC system for the cleanroom used for Arista AH packaging processes
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Apr 29, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P050038/S043
Regulatory pathway
PMA supplement
Applicant
Davol, Inc.
Product code
LMG
Decision code
OK30
Decision date
Apr 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, absorbable hemostatic, non-collagen based.

Applicant
Davol, Inc.
Product code
LMG
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P050038/S043 received

    Application receipt date recorded by FDA.

  2. P050038/S043 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P050038. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P050038

Product / regulatory recordCompanyPathwayDecision dateSource
Arista AHP050038/S044
Davol, Inc.PMA supplementJul 15, 2026FDA

Explore the linked device profile

Other records with product code LMG

Product / regulatory recordCompanyPathwayDecision dateSource
Baxter Healthcare CorporationPMA supplementNov 7, 2026FDA
ETHICON, Inc.PMA supplementNov 5, 2026FDA
Baxter Healthcare CorporationPMA supplementAug 7, 2026FDA
Baxter Healthcare CorporationPMA supplementAug 7, 2026FDA
ETHICON, Inc.PMA supplementJul 28, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Davol, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
100 Crossings Blvd., Warwick, RI, 02886

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records